Summary of "МЕНОПАУЗА и ПСИХИКА: когда назначается ГЗТ, а когда - антидепрессанты? @evropapsi"

Key ideas: How menopause affects mental health

Menopause and perimenopause are described as a neuroendocrine restructuring that affects the brain, emotions, cognition, and self-perception.
The emphasis is not only on low estrogen, but especially on rapid estrogen fluctuations, which are presented as stressful for the brain.
Estrogen is linked to brain systems involved in mood and calm, including:
- Serotonin, dopamine, GABA balance (hormone fluctuations can disrupt neurotransmitters)
- Limbic system activity, with references to the hippocampus, amygdala, and prefrontal cortex
Hormonal changes can trigger or worsen:
- Anxiety
- Depressive symptoms
- Irritability/internal tension
- Sleep disturbances
- Cognitive symptoms (“brain fog,” concentration and memory issues)

The “vicious circle”

A “vicious circle” is noted:

hormonal imbalance → sleep problems → worsening mood/anxiety → further deterioration

Risk patterns and vulnerability

Perimenopause and menopause are presented as a window of increased vulnerability:

Mood disorders: 2–5× more often
Anxiety disorders: about 1.5× more likely
Early menopause is associated (per a cited study) with roughly 2× higher risk of depression
A second peak is also mentioned for the onset of certain psychiatric illnesses during menopause/perimenopause (in comparison to an earlier youth peak)

When HRT vs. antidepressants may be considered

The speaker stresses there’s no universal rule, but offers a clinical “logic” for decision-making.

HRT may be more likely if:

Typical menopausal physical symptoms and sleep issues are prominent:
- hot flashes
- night sweats
- insomnia/sleep disturbances
Mood/anxiety symptoms appear on this backdrop and seem hormonally linked
Specialist involvement is important: HRT is framed as a decision made by a gynecologist and/or endocrinologist, not primarily by a psychiatrist

Antidepressants may be more likely if:

Symptoms fit a clinical depression picture, such as:
- persistent low mood
- loss of interest
- hopelessness
- reduced self-esteem / devaluation
- strong melancholy
- anxiety
- suicidal thoughts
The video emphasizes that antidepressants are not postponed until hormonal labs are available when depression is moderate-to-severe

A combined (“dual”) approach may be used if:

Depression is pronounced and clinically severe during menopause, or
The case is resistant/severe, especially when symptoms seem to include both hormonal and psychiatric components

Role of individual sensitivity and history

Menopause is not presented as the only cause of depression. Key modifiers include:

Individual genetic sensitivity
Past psychiatric history (prior depression increases recurrence risk during menopause)
Current life circumstances/stressors (e.g., major life transitions)

If someone has no prior psychiatric episodes, symptoms arising during hormone instability may be more transient—though the video still implies that professional evaluation is important when needed.

Self-care / wellness-adjacent takeaways

Address sleep disruption early, since it can fuel the anxiety/depression cycle.
Seek evaluation from the right specialist based on the suspected driver:
- HRT-related symptoms → gynecologist/endocrinologist
- Clinical depression/anxiety severity → psychiatric treatment (including antidepressants when indicated)

Presenters or sources

Presenter: Sofía Rothermel — European licensed physician; PhD in molecular medicine; host of @evropapsi / “European Psychiatry”
Sources mentioned (general):
- “Large studies” on perimenopause/menopause and mood/anxiety disorder rates
- A study on early menopause and depression risk (about 2×)
- 2024 data from a specialized Canadian menopause-focused clinic
- Study examples comparing:
  - estradiol vs antidepressants (50 women mentioned)
- ICD-11 note: classification approach to depression based on symptoms over the last 2 weeks